XML 27 R13.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Stockholders’ Equity and Stock-Based Compensation | 12 Months Ended
--- | ---
Dec. 30, 2023
Equity [Abstract] |
Stockholders’ Equity and Stock-Based Compensation | 6. Stockholders’ Equity and Stock-Based Compensation Registered Sale of Equity Securities In the first quarter of fiscal year 2021, the Company sold 2.4 million shares of common stock for gross proceeds of $16 million (average of $6.66 per share), before deducting broker expenses paid by the Company of $0.5 million pursuant to the Company’s At-The-Market Equity Offering Sales Agreement dated as of February 8, 2019 (the “Previous ATM Agreement”) with Stifel, Nicolaus & Company, Incorporated, (“Stifel”) as agent. In the second quarter of 2021, the Company sold 0.1 million shares of common stock for gross proceeds of $0.8 million (average of $6.74 per share), before deducting broker expenses paid by the Company of $0.1 million under the Previous ATM Agreement. The Previous ATM Agreement has since terminated pursuant to its terms as a result of the sale of all the shares subject to such agreement. On March 5, 2021, the Company entered into a new At-The-Market Equity Offering Sales Agreement (the “Current ATM Agreement”) with Stifel under which the Company may sell up to $50 million of the Company’s common stock. In the third quarter of 2021, the Company sold 0.6 million shares of common stock for gross proceeds of $4.8 million (average of $8.06 per share), before deducting broker expenses paid by the Company of $0.1 million under the Current ATM Agreement. In the second quarter of 2022, the Company sold 1.5 million shares of common stock and 0.2 million shares of treasury stock for gross proceeds of $2.1 million (average of $1.26 per share) before deducting broker expenses paid by the Company of less than $0.1 million and in the third quarter of 2022, the Company sold 675,000 shares of common stock for gross proceeds of approximately $0.9 million (average of $1.27 per share) before deducting broker expenses paid by the Company of less than $0.1 million, pursuant to the Current ATM Agreement. The net proceeds from the sale of common shares were used for general corporate purposes, including working capital. On January 27, 2023, the Company sold 17 million shares of registered common stock and issued pre-funded warrants to purchase up to 6,000,000 shares of common stock at a public offering price of $0.99 per pre-funded warrant, for gross proceeds of $22.9 million before deducting underwriting discounts and offering expenses paid by the Company of $1.5 million. The offering price of the pre-funded warrant equals the public offering price per share of the common stock less the $0.01 per share exercise price of each pre-funded warrant. At December 30, 2023, the Company had available $41.4 million for sale of common stock under the Current ATM Agreement. Sale of Treasury Stock During the year ended December 31, 2022, the Company sold 126,389 shares of its common stock for approximately $0.2 million through the sale of shares under its At The Market Offering Agreement, dated March 5, 2021. Commissions paid were less than $10,000. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED) Restricted Stock Awards In 2020, the Company adopted the 2020 Equity Incentive Plan (“2020 Equity Plan”) which authorized the issuance of shares of common stock to employees, certain consultants and advisors who perform services for the Company, and non-employee members of the Board. The 2020 Equity Plan is a successor to the Company’s 2010 Equity Incentive Plan (“2010 Equity Plan”). The number of shares authorized under the 2020 Equity Plan was 4,000,000 shares of common stock, which has since been amended to authorize the issuance of 11,000,000 shares of common stock. In addition, shares of common stock underlying any outstanding award granted under the 2010 Equity Plan that expires, or is terminated, surrendered or forfeited for any reason without issuance of such shares shall be available for the award of new Grants under this Plan. As of December 30, 2023, the Company has approximately 5.8 million shares of common stock authorized and available for issuance under the Company’s 2020 Equity Plan. The fair value of non-vested restricted common stock awards is generally the market value of the Company’s common stock on the date of grant. The non-vested restricted common stock awards require the employee to fulfill certain obligations, including remaining employed by the Company for periods ranging from one to five years (the vesting period) and in certain cases also require meeting either performance criteria or the Company’s stock achieving a certain price. For non-vested restricted common stock awards that solely require the recipient to remain employed with the Company, the stock compensation expense is amortized over the anticipated service period. For non-vested restricted common stock awards that require the achievement of performance criteria, the Company reviews the probability of achieving the performance goals on a periodic basis. If the Company determines that it is probable that the performance criteria will be achieved, the amount of compensation cost derived for the performance goal is amortized over the anticipated service period. If the performance criteria are not met, no compensation cost is recognized and any previously recognized compensation cost is reversed. Schedule of Non-vested Restricted Stock Activity
|  | Shares |  |  | Weighted Average Grant Fair Value |
Balance at December 25, 2021 |  |  | 2,077,592 |  |  | $ | 2.90 |
Granted |  |  | 1,013,600 |  |  |  | 1.33 |
Forfeited |  |  | (444,350 | ) |  |  | 2.45 |
Vested |  |  | (680,941 | ) |  |  | 2.82 |
Balance at December 31, 2022 |  |  | 1,965,901 |  |  |  | 2.22 |
Granted |  |  | 3,423,531 |  |  |  | 1.58 |
Forfeited |  |  | (1,089,773 | ) |  |  | 2.52 |
Vested |  |  | (2,367,892 | ) |  |  | 1.62 |
Balance at December 30, 2023 |  |  | 1,931,767 |  |  | $ | 1.65 |
On December 31, 2020 (fiscal year 2021), the Company amended the employment agreement with its former CEO, and as part of the amendment issued five tranches of 188,000 shares of restricted stock grants. The Company used a Monte Carlo model to determine the estimated fair value of the awards. Total compensation expense resulting from the awards is approximately $2.1 million. The Company’s stock price met the required levels in the first quarter of fiscal year 2021 and the total stock compensation expense was recognized in the first quarter of fiscal year 2021. The following table describes inputs used to calculate fair value of the restricted stock grants: Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions
Expected volatility |  |  | 94.2 | %
Interest rate |  |  | 0.2 | %
Expected life (years) |  |  | 0.7 |
Dividend yield |  |  | — | %
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED) Stock-Based Compensation The following table summarizes stock-based compensation expense within each of the categories below as it relates to non-vested restricted common stock awards for the fiscal years 2023, 2022 and 2021 (no tax benefits were recognized): Schedule of Stock-based Compensation Expense
|  | 2023 |  |  | 2022 |  |  | 2021 |
Cost of product revenues |  | $ | 1,210,453 |  |  | $ | 94,634 |  |  | $ | 211,362 |
Research and development |  |  | 861,324 |  |  |  | 435,842 |  |  |  | 576,193 |
Selling, general and administrative |  |  | 1,803,496 |  |  |  | 737,229 |  |  |  | 3,629,867 |
Total |  | $ | 3,875,273 |  |  | $ | 1,267,705 |  |  | $ | 4,417,422 |
Unrecognized compensation expense for non-vested restricted common stock as of December 30, 2023 totaled $3.2 million and is expected to be recognized over a weighted average period of approximately four years.

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//505/tableOfContent Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//718/tableOfContent + Details
Name: | us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration